European Commission proposes extension of Medical Devices Regulation transition period in bid to prevent medical device shortages

At the Employment, Social Policy, Health and Consumer Affairs (EPSCO) meeting on 09 December 2022, the European Commissioner for Health and Safety, Stella Kyriakides, put forward proposals in her opening speech to extend the transition rules of the Medical Devices Regulation (EU) 2017/745. The Medical Devices Regulation (MDR) was adopted by the European Parliament and […]

What is a Target Product Profile and when is it needed?

When embarking on a journey it is preferable to have a destination or end goal in mind. The same is true when developing biopharmaceutical products; having an end goal or milestone to target helps keep the project team focused on what is required to reach the desired endpoint. A Target Product Profile (TPP), as the […]

Mitigating the risks with scientific due diligence

The need for scientific due diligence When companies enter into a deal, the successful outcome of that deal is subject to both parties working together to share information until an agreement can be reached. For biotech and life sciences companies, this is often achieved through scientific due diligence. Due diligence carries the simple understanding; you […]

Navigating the challenges faced by Medical Directors

The role of a Medical Director is not only the key to the success of the medical department but secures medical as a key strategic Partner. This however is not always straightforward to achieve with competing priorities and views. Our experienced team has first-hand experience with the challenges faced by Medical Directors every day. Dr […]

Medical monitors in clinical trials: the linchpin between patients and sponsors

Medical monitoring is an essential component of clinical trials: ensuring participant safety and data integrity. This medical oversight is often thought of as part of the sponsor team, our independent medical monitors (MM) at Boyds work on behalf of the sponsor, providing oversight across multiple study sites or multiple separate clinical trials. Boyds has a […]

Reflecting on my first six months at Boyds – a blog by Dr Neil Fish

Dr Neil Fish joined Boyds in November 2021 as Vice President of Business Development, and has subsequently established the business development function, bringing in the required skills and best practise to support the development of new opportunities for Boyds. In his blog, Neil reflects on his first six months. My first six months at Boyds […]

Progress of cell and gene therapies

Huge leaps forward in the development of cell and gene therapies have been made over the past few years, progressing the development of new treatments for diseases that were considered untreatable only a decade ago. In recent weeks there has been a significant flow of positive news about different types of advanced therapies.  It was […]

UK continues to lead in Advanced Therapies

The latest data on Advanced Therapy clinical trials has been released by the Cell and Gene Therapy Catapult recently (March 2022), showing that the UK was delivering 12% of the total ATMP clinical trials globally1. There is continued steady growth from 2017 to 2021 with the latest full-year having 168 trials ongoing versus 154 in […]